ChengDa Pharmaceuticals Co. Ltd. (301201) — Cash Flow Reinvestment Rate

Latest as of December 2024: 42.29x

ChengDa Pharmaceuticals Co. Ltd. (301201) has a Cash Flow Reinvestment Rate of 42.29x as of December 2024, reinvesting CN¥1.21 Billion (capex CN¥286.36 Million plus investments CN¥-925.26 Million) from operating cash flow of CN¥28.65 Million. Check ChengDa Pharmaceuticals Co. Ltd. (301201) cash flow quality to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

42.29x
(Capex + Investments) / Operating CF

Total Reinvested

CN¥1.21 Billion
Capex + Investments

Operating Cash Flow

CN¥28.65 Million
CNY

Capital Expenditures

CN¥286.36 Million
CNY

ChengDa Pharmaceuticals Co. Ltd. Cash Flow Reinvestment Rate (2019–2024)

Historical reinvestment intensity for ChengDa Pharmaceuticals Co. Ltd. across 6 annual periods. Explore 301201 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.

Annual Cash Flow Reinvestment Rate for ChengDa Pharmaceuticals Co. Ltd. (2019–2024)

Year-by-year capital reinvestment analysis for ChengDa Pharmaceuticals Co. Ltd.. For live market cap and broader valuation context, see ChengDa Pharmaceuticals Co. Ltd. (301201) market capitalisation.

Year Reinvestment Rate Total Reinvested (CNY) Operating CF Capex YoY Change
2024 42.29x CN¥1.21 Billion CN¥28.65 Million CN¥286.36 Million ▲ +678.6%
2023 5.43x CN¥1.04 Billion CN¥192.07 Million CN¥224.67 Million ▼ -78.3%
2022 25.06x CN¥1.19 Billion CN¥47.67 Million CN¥205.69 Million ▲ +651.3%
2021 3.34x CN¥277.28 Million CN¥83.14 Million CN¥138.70 Million ▲ +481.4%
2020 0.57x CN¥73.99 Million CN¥128.97 Million CN¥63.81 Million ▼ -60.8%
2019 1.46x CN¥98.73 Million CN¥67.52 Million CN¥51.06 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow